Enzolytics, Inc. (OTCMKTS:ENZC) Short Interest Update

Enzolytics, Inc. (OTCMKTS:ENZC) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 677,542 shares, an increase of 324,082.8% from the January 15th total of 209 shares. Based on an average daily volume of 7,284,850 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 7,284,850 shares, the days-to-cover ratio is currently 0.1 days.

Enzolytics Price Performance

Enzolytics stock remained flat at $0.00 during midday trading on Tuesday. The company had a trading volume of 4,233,549 shares, compared to its average volume of 5,148,373. Enzolytics has a 52 week low of $0.00 and a 52 week high of $0.00.

About Enzolytics

Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.

In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.